Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 6/20 | 0.38 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.38 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482143 | 0.86 | KMT2A (0.48) | KMT2ATLR2TLR1HDAC3HDAC1 | |
| SCHEMBL22127872 | 0.84 | KMT2A (0.48) | KMT2ATLR2TLR1MDM2 | |
| SCHEMBL29482173 | 0.84 | TLR2 (0.51) | KMT2ATLR2TLR1HDAC1HDAC6 | |
| SCHEMBL29653639 | 0.83 | KMT2A (0.50) | KMT2ATLR2TLR1HDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL29482139 | 0.83 | KMT2A (0.49) | KMT2ATLR2TLR1HDAC3HDAC1 | |
| SCHEMBL29482156 | 0.82 | KMT2A (0.48) | KMT2ATLR2TLR1 | |
| SCHEMBL22127931 | 0.82 | KMT2A (0.46) | KMT2ATLR2TLR1 | |
| SCHEMBL22127935 | 0.82 | KMT2A (0.46) | KMT2ATLR2TLR1 | |
| SCHEMBL22127932 | 0.82 | KMT2A (0.46) | KMT2ATLR2TLR1 | |
| SCHEMBL23039340 | 0.82 | TLR2 (0.42) | KMT2ATLR2TLR1FDFT1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988561-B1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| EP-3988561-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2022-04-27 | — | — | EP | disclosed |
| US-11312703-B2 | Reactive oxygen species scavengers and use for treating diseases | XWPharma Ltd. (KY) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312703-B2 | Reactive oxygen species scavengers and use for treating diseases | GSR, TXNRD2, GPX1 | KMT2A 4439/4885TLR2 3086/4885TLR1 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.